All Releases
 |
Capstone Therapeutics Provides Operating Update and Announces 2011 Financial Results
Mar 21, 2012
|
25.0 KB |
|
| |
TEMPE, Ariz., March 21, 2012 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (the "Company") provided an operating update and announced financial results for 2011.
OPERATING UPDATE
We previously announced that:
On October 13, 2011, the Company's Board of Directors adopted a plan to preserve cash during our ongoi...
|
|
Capstone Therapeutics Announces Operational Update
Jan 20, 2012
|
22.3 KB |
|
| |
TEMPE, Ariz., Jan. 20, 2012 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) (the "Company") announced today additional steps it has taken to preserve cash and move toward winding down operations.
Capstone will cease clinical development of AZX100, its principal drug candidate, in dermal scarring. Certain pre-clinical, manufacturing a...
|
|
Capstone Therapeutics Announces Plan to Preserve Cash During Ongoing Partnering Efforts
Oct 14, 2011
|
24.9 KB |
|
| |
TEMPE, Ariz., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today its plan to preserve cash during ongoing discussions with potential partners regarding AZX100 in dermal scarring. The Company will reduce staff from its current 18 full-time employees to a core of four individuals covering required re...
|
|
Capstone Therapeutics to Hold Quarterly Update Conference Call
Aug 23, 2011
|
25.0 KB |
|
| |
TEMPE, Ariz., Aug. 23, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), today will hold a conference call and webcast to provide a quarterly Company update.
Conference Call Information
Management will host a conference call and webcast today, Tuesday, August 23, 2011 at 1:00 pm EST / 10:00 am PST. The ca...
|
|
Capstone Therapeutics to Host Quarterly Update Conference Call
Aug 19, 2011
|
24.9 KB |
|
| |
TEMPE, Ariz., Aug. 19, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) (the "Company") will host a conference call and webcast on Tuesday, August 23, 2011 at 1:00 pm EDT / 10:00 am PDT. The call may be accessed at 877-303-9204 (U.S.), 760-536-5225 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of...
|
|
Capstone Therapeutics Announces Pre-Clinical Results With AZX100 in Radiation and Bleomycin Models of Pulmonary Fibrosis; Pulmonary Anti-Fibrotic Effect Demonstrated
Jul 6, 2011
|
26.8 KB |
|
| |
TEMPE, Ariz., July 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced results from a pre-clinical study of AZX100 in a rodent model of radiation-induced pulmonary fibrosis.
Using the TUNEL assay — an established method for detecting DNA fragments that are the hallmark of "programmed c...
|
|
Capstone Therapeutics Announces Adjournment of Its Annual Meeting of Stockholders and Intention to Reconvene the Meeting on June 28, 2011
Jun 8, 2011
|
22.7 KB |
|
| |
TEMPE, Ariz., June 8, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced that at its Annual Meeting held on Monday June 6, 2011, there were insufficient shares represented by person or by proxy at the meeting to establish a quorum for the election of directors. Accordingly, the meeting was adjourned and scheduled...
|
|
Capstone Therapeutics Signs Alliance With BiolineRx to Develop Chrysalin (TP508) in Acute Myocardial Infarction
May 31, 2011
|
25.8 KB |
|
| |
TEMPE, Ariz., May 31, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced a material transfer agreement with BiolineRx (Jerusalem) to develop Chrysalin (TP508) in pre-clinical models of acute myocardial infarction (AMI). The goal of these studies is to further demonstrate the potential cardiovascular benefit...
|
|
Capstone Therapeutics Reminds Stockholders of Annual Meeting on June 6, 2011 and Encourages All Stockholders to Vote
May 26, 2011
|
22.4 KB |
|
| |
TEMPE, Ariz., May 26, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") reminds stockholders that its Annual Meeting is scheduled for Monday June 6, 2011 and encourages all eligible stockholders (stockholders of record on April 21, 2011) to vote. Brokers are no longer allowed to vote without instructions on the election o...
|
|
Capstone Therapeutics Confirms Early Signal of AZX100 Effect Based on Final Results of Phase 2a Pilot Clinical Trial in Surgical (Trocar Site) Scarring
Apr 27, 2011
|
29.4 KB |
|
| |
TEMPE, Ariz., April 27, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced that the final results from its AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring confirmed the early signal of effect observed in the interim analysis previously announced. The Company plans to continue its eff...
|
|
Capstone Therapeutics Announces Update to Timing of Release of Final Results From AZX100 Phase 2a Pilot Clinical Trial in Surgical (Trocar Site) Scarring
Apr 4, 2011
|
25.5 KB |
|
| |
TEMPE, Ariz., April 4, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced an update to the reporting schedule for twelve-month results from its AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.
Due to the size and complexity of the dataset, the report has been delayed beyond t...
|
|
Capstone Therapeutics to Present at Biotech Showcase 2011
Jan 6, 2011
|
24.9 KB |
|
| |
TEMPE, Ariz., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the Biotech Showcase 2011, Parc 55 Wyndham San Francisco – Union Square, 55 Cyril Magnin Street, San Francisco on Monday, January 10, 2011 at 3:15pm PST. Dana B. Shinbaum, Vice President, Business Development will provide an ove...
|
|
Capstone Therapeutics Announces Results of AZX100 Phase 2a Pilot Clinical Trials in Keloid and Surgical Scarring
Dec 13, 2010
|
31.1 KB |
|
| |
TEMPE, Ariz., Dec. 13, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid scarring and seven-month interim results of its ongoing AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.
The goals of a ...
|
|
Capstone Therapeutics to Host AZX100 Clinical Update Teleconference
Dec 8, 2010
|
24.7 KB |
|
| |
TEMPE, Ariz., Dec. 8, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS), (the "Company") will host a teleconference and webcast to discuss AZX100 clinical and other data on Tuesday, December 14, 2010 at 11:00am EST / 10:00am CST / 9:00am MST / 8:00am PST. The teleconference may be accessed at (877) 303-9204 (U.S.), (760) 536-5225 (outsid...
|
|
Capstone Therapeutics Announces Third Quarter 2010 Financial Results
Nov 10, 2010
|
31.6 KB |
|
| |
TEMPE, Ariz., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS), formerly OrthoLogic Corp., (the "Company"), today announced financial results for the third quarter of 2010.
The Company reported a net loss of $2.6 million, or $0.06 per share, for the third quarter of 2010, compared to a net loss of $3.3 million or $0.08 ...
|
|
Capstone Therapeutics to Host Quarterly Update Conference Call
Nov 3, 2010
|
24.9 KB |
|
| |
TEMPE, Ariz., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS), (the "Company") will host a conference call and webcast on Wednesday, November 10, 2010 at 10:00am EST / 9:00am CST / 8:00am MST / 7:00am PST. The call may be accessed at 877-303-9204 (domestic), 760-536-5225 (international); accompanying slides can be viewed by log...
|
|
Capstone Therapeutics to Present at 9th Annual BIO Investor Forum
Oct 1, 2010
|
15.2 KB |
|
| |
TEMPE, Ariz., Oct 1, 2010 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the 9th Annual BIO Investor Forum, Palace Hotel, 2 New Montgomery Street, San Francisco, CA on Tuesday, October 5, 2010 at 3:00pm EDT. Dana B. Shinbaum, Vice President, Business Development will provide an ...
|
|
Capstone Therapeutics Announces Progress in Clinical Trials of AZX100 in Keloid Scarring
Sep 13, 2010
|
16.3 KB |
|
| |
TEMPE, Ariz., Sep 13, 2010 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today that participating subjects have reached the planned twelve-month timepoint in the first of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. Data analysis for these subjects is underway. Per pr...
|
|
Capstone Therapeutics to Present at Rodman & Renshaw 12th Annual Healthcare Conference
Sep 7, 2010
|
15.7 KB |
|
| |
TEMPE, Ariz., Sep 7, 2010 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the Rodman & Renshaw 12th Annual Healthcare Conference, New York Palace Hotel, 455 Madison Avenue, New York 10022 on Tuesday, September 14, 2010 at 2:50pm EDT. John M. (Jock) Holliman, Executive Chairman, w...
|
|
Capstone Therapeutics Announces Second Quarter 2010 Financial Results
Aug 9, 2010
|
20.1 KB |
|
| |
TEMPE, Ariz., Aug 9, 2010 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) (formerly OrthoLogic Corp.; the "Company"), today announced financial results for the second quarter of 2010.
The Company reported a net loss of $2.9 million, or $0.07 per share, for the second quarter of 2010, compared to a net loss of $3.1...
|
|
|
